Retrospective Study
Copyright ©The Author(s) 2022.
World J Gastroenterol. Oct 14, 2022; 28(38): 5626-5635
Published online Oct 14, 2022. doi: 10.3748/wjg.v28.i38.5626
Table 1 Clinicopathologic variables of 325 T2N0M0 gastric cancer patients
Variable
Overall
Adjuvant chemotherapy group
Postoperative observation group
P value
32563262
Age (yr) n (%)0.609
< 4020 (6.2)3 (4.8)17 (6.5)
≥ 40305 (93.8)60 (95.2)245 (93.5)
Sex, n (%)0.878
Male250 (76.9)48 (76.2)202 (77.1)
Female75 (23.1)15 (23.8)60 (22.9)
Smoking history, n (%)0.363
Yes169 (52.0)36 (57.1)133 (50.8)
No156 (48.0)27 (42.9)129 (49.2)
Family history of gastric cancer, n (%)0.852
Yes24 (7.4)5 (7.9)19 (7.3)
No301 (92.6)58 (92.1)243 (92.7)
BMI, n (%)0.150
< 18.5 or > 23.9176 (54.2)29 (46.0)147 (56.1)
18.5-23.9149 (45.8)34 (54.0)115 (43.9)
Postoperative hospital stay, n (%)0.747
≤ 14 d285 (87.7)56 (88.9)229 (87.4)
> 14 d40 (12.3)7 (11.1)33 (12.6)
Tumor site, n (%)0.004
Cardia cancer105 (32.3)30 (47.6)75 (28.6)
Non-cardia gastric cancer220 (67.7)33 (52.4)187 (71.4)
The degree of differentiation, n (%)0.571
Poorly differentiated121 (37.2)24 (38.1)97 (37.0)
Moderately differentiated178 (54.8)36 (57.1)142 (54.2)
Highly differentiated26 (8.0)3 (4.8)23 (8.8)
Vascular invasion, n (%)0.014
Yes54 (16.6)17 (27.0)37 (14.1)
No271 (83.4)46 (73.0)225 (85.9)